A comparison of strategies for identifying patients at risk for carbapenem-resistant or extended β-lactam-resistant Pseudomonas aeruginosa
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae104 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Walaiporn Wangchinda und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Pseudomonas Infections, Carbapenems, Anti-Bacterial Agents. Die Arbeit nennt 16 Literaturangaben. Gefördert von: Merck Sharp & Dohme LLC, Merck & Co., Inc..
Abstract (Originalsprache)
Objectives
To assess risk factors for carbapenem-resistant Pseudomonas aeruginosa (CR) and extended-β-lactam-resistant P. aeruginosa (EBR) infection/colonization, and to develop and compare tools for predicting isolation of CR and EBR from clinical cultures.
Methods
This retrospective study analysed hospitalized patients with positive P. aeruginosa cultures between 2015 and 2021. Two case–control analyses were performed to identify risk factors and develop scoring tools for distinguishing patients with CR versus carbapenem-susceptible (CS) P. aeruginosa and EBR versus CS P. aeruginosa. The performance of institutionally derived scores, externally derived scores and the presence/absence of key risk factors to predict CR and EBR were then compared.
Results
A total of 2379 patients were included. Of these, 8.3% had a positive culture for CR, 5.0% for EBR and 86.7% for CS P. aeruginosa. There was substantial overlap in risk factors for CR and EBR. Institutional risk scores demonstrated modestly higher area under the ROC curve values than external scores for predicting CR (0.67 versus 0.58) and EBR (0.76 versus 0.70). Assessing the presence/absence of ≥1 of the two strongest predictors (prior carbapenem use or CR isolation within 90 days) was slightly inferior to scoring tools for predicting CR, and comparable for predicting EBR.
Conclusions
Clinicians concerned about CR in P. aeruginosa should consider the likelihood of EBR when making treatment decisions. A simple approach of assessing recent history of CR isolation or carbapenem usage performed similarly to more complex scoring tools and offers a more pragmatic way of identifying patients who require coverage for resistant P. aeruginosa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
- Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Department of Medicine, Rutgers University, Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
- Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA.
- Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, WI, USA.
ORCID-Profile: Walaiporn Wangchinda, Keith S Kaye, Joshua G Petrie, Jason M Pogue
Förderung
- Merck Sharp & Dohme LLC
- Merck & Co., Inc.
Zitieren
APA
Wangchinda, W., Kaye, K. S., Patel, T. S., Albin, O. R., Saravolatz, L., Petrie, J. G., & Pogue, J. M. (2024). A comparison of strategies for identifying patients at risk for carbapenem-resistant or extended β-lactam-resistant Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae104
Vancouver
Wangchinda W, Kaye KS, Patel TS, Albin OR, Saravolatz L, Petrie JG, et al. A comparison of strategies for identifying patients at risk for carbapenem-resistant or extended β-lactam-resistant Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae104
BibTeX
@article{Wangchinda2024,
author = {Wangchinda, Walaiporn and Kaye, Keith S and Patel, Twisha S and Albin, Owen R and Saravolatz, Louis and Petrie, Joshua G and Pogue, Jason M},
title = {A comparison of strategies for identifying patients at risk for carbapenem-resistant or extended β-lactam-resistant Pseudomonas aeruginosa},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae104}
}
EUVIMED